Application of Active Targeting Nanoparticles Delivery System for Drugs and Herbal Medicines with Anticancer Activities: A Systematic Review| Chapter 4 | Challenges and Advances in Pharmaceutical Research Vol.3

Patients getting conventional cancer therapy have side effects due to the non-selective action of chemotherapeutic medications on normal cells. Active targeting nanoparticles that are connected to targeting ligands on the surface of nanoparticles increase drug selectivity in cancer cells. The goal of this systematic review was to compile information on the selective delivery of anticancer pharmaceuticals and herbal remedies to cancer cells using active targeting nanoparticles. Up to March 2017, a literature search was done using the phrases nanoparticle, chemotherapy, traditional medicine, herbal medicine, and other related terms in the PubMed database. Natural medicine, a natural chemical, cancer therapy, and active targeting are all examples of natural medicine. The study comprised 61 papers out of 695 that met the predetermined inclusion and exclusion criteria. Among the ligands studied were proteins/peptides, hyaluronic acid, folic acid, antibodies/antibody fragments, aptamer, and carbohydrates/polysaccharides. In vitro and in vivo research suggest that active targeting nanoparticles outperform standard chemotherapeutic medications and non-targeted nanoparticle platforms in terms of treatment effectiveness and safety by enhancing cellular uptake selectivity and/or cytotoxicity. Clinical research, on the other hand, is required to verify these findings.

Author(s) Details:

Nadda Muhamad,
Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathumtani 12121, Thailand.

Tullayakorn Plengsuriyakarn,
Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathumtani 12121, Thailand and  Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathumtani 12121, Thailand.

Kesara Na-Bangchang,
Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathumtani 12121, Thailand and  Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathumtani 12121, Thailand.

Please see the link here: https://stm.bookpi.org/CAPRV-3/article/view/6944